127 related articles for article (PubMed ID: 38701697)
1. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis.
Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y
Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697
[TBL] [Abstract][Full Text] [Related]
2. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
[TBL] [Abstract][Full Text] [Related]
3. Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI.
Shahim P; Politis A; van der Merwe A; Moore B; Ekanayake V; Lippa SM; Chou YY; Pham DL; Butman JA; Diaz-Arrastia R; Zetterberg H; Blennow K; Gill JM; Brody DL; Chan L
Neurology; 2020 Aug; 95(6):e623-e636. PubMed ID: 32641529
[TBL] [Abstract][Full Text] [Related]
4. Matching proposed clinical and MRI criteria of aggressive multiple sclerosis to serum and cerebrospinal fluid markers of neuroaxonal and glial injury.
Schaller-Paule MA; Maiworm M; Schäfer JH; Friedauer L; Hattingen E; Wenger KJ; Weber F; Jakob J; Steffen F; Bittner S; Yalachkov Y; Foerch C
J Neurol; 2024 Jun; 271(6):3512-3526. PubMed ID: 38536455
[TBL] [Abstract][Full Text] [Related]
5. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij BH; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
[TBL] [Abstract][Full Text] [Related]
6. Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity.
Högel H; Rissanen E; Barro C; Matilainen M; Nylund M; Kuhle J; Airas L
Mult Scler; 2020 Feb; 26(2):210-219. PubMed ID: 30570436
[TBL] [Abstract][Full Text] [Related]
7. Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.
Axelsson M; Malmeström C; Nilsson S; Haghighi S; Rosengren L; Lycke J
J Neurol; 2011 May; 258(5):882-8. PubMed ID: 21197541
[TBL] [Abstract][Full Text] [Related]
8. Association of Plasma Amyloid, P-Tau, GFAP, and NfL With CSF, Clinical, and Cognitive Features in Patients With Dementia With Lewy Bodies.
Bolsewig K; van Unnik AAJM; Blujdea ER; Gonzalez MC; Ashton NJ; Aarsland D; Zetterberg H; Padovani A; Bonanni L; Mollenhauer B; Schade S; Vandenberghe R; Poesen K; Kramberger MG; Paquet C; Bousiges O; Cretin B; Willemse EAJ; Teunissen CE; Lemstra AW;
Neurology; 2024 Jun; 102(12):e209418. PubMed ID: 38830138
[TBL] [Abstract][Full Text] [Related]
9. Significance of CSF NfL and tau in ALS.
Schreiber S; Spotorno N; Schreiber F; Acosta-Cabronero J; Kaufmann J; Machts J; Debska-Vielhaber G; Garz C; Bittner D; Hensiek N; Dengler R; Petri S; Nestor PJ; Vielhaber S
J Neurol; 2018 Nov; 265(11):2633-2645. PubMed ID: 30187162
[TBL] [Abstract][Full Text] [Related]
10. Serum GFAP as a biomarker for disease severity in multiple sclerosis.
Abdelhak A; Huss A; Kassubek J; Tumani H; Otto M
Sci Rep; 2018 Oct; 8(1):14798. PubMed ID: 30287870
[TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis.
Constantinescu R; Krýsl D; Bergquist F; Andrén K; Malmeström C; Asztély F; Axelsson M; Menachem EB; Blennow K; Rosengren L; Zetterberg H
Eur J Neurol; 2016 Apr; 23(4):796-806. PubMed ID: 26822123
[TBL] [Abstract][Full Text] [Related]
12. High Levels of NfL, GFAP, TAU, and UCH-L1 as Potential Predictor Biomarkers of Severity and Lethality in Acute COVID-19.
Salvio AL; Fernandes RA; Ferreira HFA; Duarte LA; Gutman EG; Raposo-Vedovi JV; Filho CHFR; da Costa Nunes Pimentel Coelho WL; Passos GF; Andraus MEC; da Costa Gonçalves JP; Cavalcanti MG; Amaro MP; Kader R; de Andrade Medronho R; Figueiredo CP; Amado-Leon LA; Alves-Leon SV
Mol Neurobiol; 2024 Jun; 61(6):3545-3558. PubMed ID: 37996731
[TBL] [Abstract][Full Text] [Related]
13. Glial fibrillary acidic protein elevations relate to neuroimaging abnormalities after mild TBI.
Gill J; Latour L; Diaz-Arrastia R; Motamedi V; Turtzo C; Shahim P; Mondello S; DeVoto C; Veras E; Hanlon D; Song L; Jeromin A
Neurology; 2018 Oct; 91(15):e1385-e1389. PubMed ID: 30209234
[TBL] [Abstract][Full Text] [Related]
14. Serum glial fibrillary acidic protein is a predictor of brain metastases in patients with metastatic breast cancer.
Darlix A; Hirtz C; Mollevi C; Ginestet N; Tiers L; Jacot W; Lehmann S
Int J Cancer; 2021 Oct; 149(8):1605-1618. PubMed ID: 34196964
[TBL] [Abstract][Full Text] [Related]
15. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis.
Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H
J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108
[TBL] [Abstract][Full Text] [Related]
16. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic and Prognostic Value of Plasma GFAP in Sporadic Creutzfeldt-Jakob Disease in the Clinical Setting of Rapidly Progressive Dementia.
Bentivenga GM; Baiardi S; Mastrangelo A; Zenesini C; Mammana A; Rossi M; Polischi B; Capellari S; Parchi P
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791145
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament and glial fibrillary acidic protein in multiple sclerosis.
Norgren N; Sundström P; Svenningsson A; Rosengren L; Stigbrand T; Gunnarsson M
Neurology; 2004 Nov; 63(9):1586-90. PubMed ID: 15534240
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers.
Edwards KR; Kamath A; Button J; Kamath V; Mendoza JP; Zhu B; Plavina T; Woodward C; Penner N
Mult Scler Relat Disord; 2021 Jun; 51():102861. PubMed ID: 33773271
[TBL] [Abstract][Full Text] [Related]
20. Plasma neurofilament light chain and glial fibrillary acidic protein predict stroke in CADASIL.
Chen CH; Cheng YW; Chen YF; Tang SC; Jeng JS
J Neuroinflammation; 2020 Apr; 17(1):124. PubMed ID: 32321529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
